AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management’s participation in the H.C. Wainwright 27^th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City.

Rick Barry, President and Chief Executive Officer, will participate in-person at this corporate event.

Conference details are as follows:

H.C. Wainwright 27^th Annual Global Investment Conference
Format: Corporate Presentation
Date: Monday, September 8, 2025
Time: 5 PM ET
Webcast Link: Here

A replay of the webcast will be accessible on the Cassava Investor’s website for approximately 90 days following the event.

To request a meeting or for more details about the conference please reach out to your institutional contact.

About Cassava Sciences, Inc.

Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications. Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A protein, which regulates diverse aspects of neuronal development. The Company is based in Austin, Texas.

For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:

Investors
Sandya von der Weid
This email address is being protected from spambots. You need JavaScript enabled to view it.

Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.